Navigation Links
OxThera Raises Capital for Further Clinical Development of Oxabact(R)
Date:9/19/2012

STOCKHOLM, September 19, 2012 /PRNewswire/ --

OxThera AB has successfully raised MSEK 39 in a rights issue. The proceeds from the financing will enable OxThera to complete a new clinical study to confirm the positive effects of treatment with Oxabact® previously seen in patients with Primary Hyperoxaluria, a debilitating medical condition for which there is no effective treatment today.

"We appreciate the continued support from our shareholders, including HealthCap, Industrifonden and Q-Med[1], as well as their strong belief in Oxabact®", says Elisabeth Lindner, CEO of OxThera. "Our mapping of OxThera's previous scientific and clinical findings has resulted in an improved medical product that will support a regulatory filing for a confirmatory clinical trial later this year." Elisabeth Lindner continues.

OxThera holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria. Oxabact® is an oral product composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes), administered in capsules. The drug is designed for delivery in the lower part of the small intestine, where enteric elimination of endogenous oxalate is initiated. OxThera is currently discussing a complete Oxabact® clinical development plan with regulatory agencies in the EU and in the US for the treatment of patients suffering from Primary Hyperoxaluria.

About primary hyperoxaluria

Primary hyperoxaluriais a rare inborn autosomal genetic disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including kidney stone formation and/or calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death. There is a high medical need for effective treatments of Primary Hyperoxaluria. Currently, the only available cure is a combined liver and kidney transplantation.

OxThera estimates that there are about 2,000 patients with Primary Hyperoxaluria in the Western world. Oxabact® holds orphan drug designations in the EU and the US for the treatment of primary hyperoxaluria.

About OxThera

OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of primary hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria.

For further information, please contact: Elisabeth Lindner, CEO of OxThera AB, Phone +46-8-660 0223

http://www.oxthera.com

--------------------------------------------------

1. A division of Galderma.


'/>"/>
SOURCE OxThera
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
4. Cerecor Raises $22 Million Series A Financing
5. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
6. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
7. Juventas Therapeutics Raises $22.2 Million Series B Financing
8. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
9. Safeway Raises Over $9 Million to Fund Prostate Cancer Research
10. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... the results of its 2016 Annual General Meeting, which was ... China . At the Annual ... of KPMG Huazhen LLP as the independent auditors of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building ... team building events, new program offerings and company expansion. , This is ... to include groups of over 30 people. Ever since, Lajollacooks4u has seen significant demand ...
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 ... Company, has expanded its customisable SureSeq™ NGS panel range with ... - allowing fast and cost-effective study of variants in familial ... copy number variation (CNV) detection on a single small panel ... and hotspot content. This includes all exons for LDLR ...
Breaking Biology Technology:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today introduced ... and their trainers non-invasively measure hemoglobin, Oxygen ... Rate, and Respiration Rate in approximately 30 seconds. Smaller ... easy and immediate access to key data about their ... a training regimen. Hemoglobin carries oxygen ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):